07 October 2021 11:00 AM
WEBINAR: Lecture series Cancer Research: "Role of mRNA Translation in Melanoma Biology and Therapeutics" - Prof Caroline Robert
LIH leukaemia project to be supported by “Marie Sklodowska-Curie Individual Fellowships”
Dr Pablo Elias Morande, postdoctoral fellow within the Tumor Stroma Interactions (TSI) research group at the LIH Department of Oncology (DONC), has been awarded financial support in the framework of the European Commission’s “Marie Sklodowska-Curie Individual Fellowships” funding scheme with an exceptional score of 99.2%. The grant will back the scientist’s work on the elucidation of some of the specific mechanisms underlying chronic lymphocytic leukaemia (CLL), thereby advancing the understanding of tumour progression and improving therapy response.
LISER and LIH to fight cardio-metabolic diseases in Luxembourg
The Luxembourg Institute of Socio-Economic Research (LISER) and the Luxembourg Institute of Health (LIH) are joining forces in the fight against cardio-metabolic diseases in Luxembourg in the framework of the FNR-funded MET'HOOD (Time-varying residential neighbourhood effects on cardio-metabolic health) project. This multidisciplinary research study is carried out by a team of geographers, epidemiologists, nutritionists and experts in physical activity and sports, with the support of local and national public health and regional planning players.
From CON-VINCE to ORCHESTRA
In April 2020, the CON-VINCE project was launched to capture the COVID-19 spread in Luxembourg. Now, in the footsteps of its predecessor, ORCHESTRA Luxembourg builds on this work to follow the immune response to COVID-19 vaccination over time and to provide evidence for the prevention and treatment of infections caused by SARS-CoV-2.
An apple a day: Could diet be used to manage autoimmune diseases?
Autoimmune diseases are a hallmark of many modern societies, with onset and progression driven by intestinal barrier dysfunction and a breakdown in normal host–microbiome interactions. Existing autoimmune disease therapies do not consider the influence of the gut microbiome in pathogenesis, which could limit their ability to alter disease progression. A collaboration between the Luxembourg Institute of Health (LIH) and the US University of Michigan Medical School, led by Prof Desai of the LIH, has published a comprehensive Perspective, in the prestigious journal Nature Reviews Gastroenterology and Hepatology, that argues that emerging personalised medicine approaches should embrace diet-assisted microbiome engineering tools to precisely remodel the microbiome towards a disease-resistant, homeostatic state.